Abbott Laboratories (ABT)

NYSE: ABT · IEX Real-Time Price · USD
-0.46 (-0.41%)
At close: Feb 3, 2023, 4:02 PM
+0.18 (0.16%)
After-hours: Feb 3, 2023, 7:59 PM EST
Market Cap 194.91B
Revenue (ttm) 45.03B
Net Income (ttm) 7.89B
Shares Out 1.74B
EPS (ttm) 4.43
PE Ratio 25.23
Forward PE 25.13
Dividend $1.88 (1.68%)
Ex-Dividend Date Jan 12, 2023
Volume 2,982,681
Open 111.81
Previous Close 112.25
Day's Range 110.66 - 112.33
52-Week Range 93.25 - 130.79
Beta 0.67
Analysts Buy
Price Target 122.18 (+9.29%)
Earnings Date Jan 25, 2023

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipi... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1888
Employees 113,000
Stock Exchange NYSE
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2021, ABT's revenue was $43.08 billion, an increase of 24.47% compared to the previous year's $34.61 billion. Earnings were $7.07 billion, an increase of 57.31%.

Financial Statements

Analyst Forecast

According to 29 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $122.18, which is an increase of 9.29% from the latest price.

Price Target
(9.29% upside)
Analyst Consensus: Buy
Stock Forecasts


ZBH vs. ABT: Which Stock Is the Better Value Option?

ZBH vs. ABT: Which Stock Is the Better Value Option?

Other symbols: ZBH
3 days ago - Zacks Investment Research

Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?

Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projec...

Other symbols: JNJ
1 week ago - MarketBeat

Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare ...

1 week ago - Zacks Investment Research

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective t...

1 week ago - PRNewsWire

Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down

The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.

1 week ago - Zacks Investment Research

Abbott Laboratories tops Q4 earnings

Yahoo Finance's Anjalee Khemlani joins the Live show to break down fourth-quarter earnings for Abbott Laboratories.

1 week ago - Yahoo Finance

Abbott (ABT) Q4 Earnings and Revenues Top Estimates

Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Abbott Revenue Falls on Decline in Covid-Related Sales

Abbott reports fourth-quarter adjusted earnings that beat Wall Street estimates but sales fall 12% from a year earlier.

1 week ago - Barrons

Abbott beats earnings, revenue expectations in Q4

Abbott Laboratories ABT had better-than-expected earnings and revenue in the fourth quarter of 2022, though headwinds from its baby formula business and declining COVID-19 test sales are still weighin...

1 week ago - Market Watch

Abbott's medical device sales hit by China curbs, supply-chain issues

Abbott Laboratories on Wednesday reported lower-than-expected medical device sales in the fourth quarter as COVID-19 curbs in China and supply-chain issues hit its international operations, dragging s...

1 week ago - Reuters

Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent Full-year 2022 GAAP diluted EPS of $3.91; a...

1 week ago - PRNewsWire

Earnings Exchange: KMB, ABT & MSFT

David Katz, Matrix Asset Advisors CIO, joins ‘The Exchange' to discuss a few stocks ahead of earnings, including Kimberly-Clark, Abbott and Microsoft.

Other symbols: MSFTKMB
1 week ago - CNBC Television

Will Abbott Stock Rise After Its Q4 Results?

For perspective, Abbott expects total Covid-19 related sales of $500 million in Q4, compared to $2.3 billion in the prior-year quarter.

1 week ago - Forbes

Final Trades: Abbott Labs, GE Healthcare, Viper Energy and more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: GEHCVNOMQCOM
1 week ago - CNBC Television

Abbott's (ABT) New FDA Approval to Improve Patient Outcome

Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.

1 week ago - Zacks Investment Research

Abbott Under Federal Investigation Over Baby Formula—Here's How The Pharmaceutical Giant Got Here

The FDA found multiple unsanitary conditions at Abbott's plant in Michigan last year, following its recall of its baby formula, prompting a nationwide shortage.

2 weeks ago - Forbes

Abbott faces U.S. criminal probe over baby formula -WSJ

Abbott Laboratories' Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday.

2 weeks ago - Reuters

Abbott facing criminal investigation over baby-formula plant operations

The Justice Department is investigating conduct at the Abbott Laboratories infant-formula plant in Sturgis, Mich., that led to its shutdown last year and worsened a nationwide formula shortage, people...

2 weeks ago - Market Watch

Abbott Under Criminal Investigation Over Baby Formula

Federal prosecutors are probing conduct at Abbott's baby-formula plant in Michigan, which the company temporarily shutdown last year after a potentially deadly bacteria was found

2 weeks ago - WSJ

Why Abbott (ABT) is Poised to Beat Earnings Estimates Again

Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago - Zacks Investment Research

ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Abbott Laboratories (NYSE: ABT) on behalf of lo...

2 weeks ago - Business Wire

Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.

2 weeks ago - Zacks Investment Research

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant  Transcatheter aortic valve implantation (TAVI) ...

2 weeks ago - PRNewsWire

Final Trades: Abbott Labs, SL Green, Zoetis & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: SLGZTSJPM
3 weeks ago - CNBC Television